<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403713</url>
  </required_header>
  <id_info>
    <org_study_id>KFL1503</org_study_id>
    <secondary_id>2013-000045-39</secondary_id>
    <nct_id>NCT02403713</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Open-label, 2-group PK (3-period) and PD (5-period) Crossover Study to Compare Systemic Exposure and Pharmacodynamic Effects of Fluticasone/Formoterol BAI and pMDI in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-group healthy volunteer study to compare a breath actuated inhaler (BAI) and a
      pressurised metered dose inhaler (pMDI) with and without spacer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 will assess pharmacokinetics, Group 2 will assess pharmacodynamics. PK interim
      analysis to determine requirement for PK extension.

      Group 1 (PK) blood sampling and safety assessments up to 36 hours post-dose for 3 study
      periods. Results from PK stage will determine if Group 2 (PD) is required. Group 2 (PD) will
      assess LABA only effects (as confirmed in interim analysis).

      Group 2 (PD) to include 2 overnight stays for 5 study periods. Volunteers will receive a
      single dose of study medication, with discharge on Day 2.

      Study treatments are fluticasone/formoterol BAI, fluticasone/formoterol pMDI with/without
      spacer, formoterol alone without spacer, and low dose fluticasone/formoterol without spacer.

      Volunteers will undergo blood sampling, and safety assessments up to the morning of
      discharge. An inspiratory flow recorder (IPR) will be used for training and to monitor
      inspiratory flow rate, inhaled volume and inhalation technique.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters Composite measurement of Pharmacokinetic parameters (Cmax, AUCt, AUCINF).</measure>
    <time_frame>Pre dose to 36 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Potassium</measure>
    <time_frame>Pre Dose to 6 hours post first dose</time_frame>
    <description>Maximum reduction in serum potassium from pre-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Pre Dose to 6 hours post dose</time_frame>
    <description>Composite measurement of vital signs (heart rate and blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glucose</measure>
    <time_frame>Pre Dose to 6 hours post dose</time_frame>
    <description>Maximum increase in Serum Glucose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Test Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone/formoterol 125/5 µg BAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone/formoterol 125/5 µg pMDI with spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone/formoterol 125/5 µg pMDI without spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol (12 µg) without spacer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/formoterol BAI</intervention_name>
    <description>Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)</description>
    <arm_group_label>Test Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol</description>
    <arm_group_label>Active Comparator 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/formoterol PMDI without spacer</intervention_name>
    <description>Fluticasone/Formoteral 125/5µg pMDI without spacer</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/formoterol PMDI with spacer</intervention_name>
    <description>Fluticasone/Formoteral 125/5µg pMDI with spacer</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/formoterol PMDI without spacer low dose</intervention_name>
    <description>Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose</description>
    <arm_group_label>Active Comparator 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 years or over.

          -  Healthy and free of significant abnormal findings as determined by medical history,
             physical examination, vital signs, laboratory tests and ECG.

          -  Normal lung function (FEV1 &gt;90% of predicted normal value).

          -  Demonstrate satisfactory technique in the use of the study drug devices.

          -  No use of steroid medication (systemic or topical) within 8 weeks prior to study
             screening.

        Exclusion Criteria:

          -  Subjects who use any asthma medication or are knowingly regularly exposed to asthma
             medication.

          -  Any history of drug or alcohol abuse.

          -  Any history of conditions that might interfere with drug absorption, distribution,
             metabolism or excretion.

          -  History of asthma, COPD, or other bronchial or lung diseases.

          -  User of steroid medication (systemic or topical) within 8 weeks prior to study
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

